Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: A pilot study

World Journal of Gastroenterology

Volumn 13, Issue 41, 2007, Pages 5465-5470

  Ishikawa, Toru ^a   Imai, Michitaka ^a   Kamimura, Hiroteru ^a   Tsuchiya, Atsunori ^a   Togashi, Tadayuki ^a   Watanabe, Kouji ^a   Seki, Kei Ichi ^a   Ohta, Hironobu ^a   Yoshida, Toshiaki ^a   Kamimura, Tomoteru ^a  

^a Saiseikai Niigata Second Hospital   (Japan)

Author keywords

Hepatocellular carcinoma; Intra arterial regional chemotherapy; Portal vein tumor thrombus

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; HISTAMINE H2 RECEPTOR ANTAGONIST; UFT;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG RESPONSE; DRUG TOLERABILITY; ENTERIC COATED TABLET; FEMALE; HAIR LOSS; HUMAN; KIDNEY INJURY; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER INJURY; MALE; MULTIPLE CYCLE TREATMENT; PILOT STUDY; PORTAL VEIN THROMBOSIS; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STOMACH ULCER; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TUMOR THROMBUS; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; VOMITING; XEROSTOMIA;

EID: 35349004121     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i41.5465     Document Type: Article

References (30)

1. Okuda K. Hepatocellular carcinoma: recent progress. Hepatology 1992; 15:948-963
2. Ichida T, Van Thiel DH, Hassanein T. The medical management of hepatocellular carcinoma (HCC) in Japan: a review with implications for HCC seen in the west. Hepatogastroenterology 1996; 43:1575-1583
3. Livraghi T, Lazzaroni S, Meloni F. Radiofrequency thermal ablation of hepatocellular carcinoma. Eur J Ultrasound 2001; 13: 159-166
4. Obi S, Yoshida H, Toune R, Unuma T, Kanda M, Sato S, Tateishi R, Teratani T, Shiina S, Omata M. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106:1990-1997
5. Sakon M, Nagano H, Dono K, Nakamori S, Umeshita K, Yamada A, Kawata S, Imai Y, Iijima S, Monden M. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94:435-442
6. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, Bru C, Rodes J, Bruix J. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29:62-67
7. Villa E, Moles A, Ferretti I, Buttafoco P, Grottola A, Del Buono M, De Santis M, Manenti F. Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology 2000; 32:233-238
8. Ishikawa T, Ichida T, Ishimoto Y, Yokoyama J, Nomoto M, Ebe Y, Usuda H, Naito M, Asakura H. Complete remission of multiple hepatocellular carcinomas associated with hepatitis C virus-related, decompensated liver cirrhosis by oral administration of enteric-coated tegafur/uracil. Am J Gastroenterol 1999; 94:1682-1685
9. Ishikawa T, Ichida T, Sugitani S, Tsuboi Y, Genda T, Sugahara S, Uehara K, Inayoshi J, Yokoyama J, Ishimoto Y, Asakura H. Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma. J Gastroenterol Hepatol 2001; 16:462-459
10. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954; 30:969-977
11. Patt YZ, Yoffe B, Charnsangavej C, Pazdur R, Fischer H, Cleary K, Roh M, Smith R, Noonan CA, Levin B. Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b. Cancer 1993; 72:2574-2582
12. Urabe T, Kaneko S, Matsushita E, Unoura M, Kobayashi K. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma. Oncology 1998; 55:39-47
13. Ota H, Nagano H, Sakon M, Eguchi H, Kondo M, Yamamoto T, Nakamura M, Damdinsuren B, Wada H, Marubashi S, Miyamoto A, Dono K, Umeshita K, Nakamori S, Wakasa K, Monden M. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 2005; 93:557-564
14. Yodono H, Sasaki T, Tarusawa K, Midorikawa H, Saito Y, Takekawa SD. Arterial infusion chemotherapy for advanced hepatocellular carcinoma using EPF and EAP therapies. Cancer Chemother Pharmacol 1992; 31 Suppl: S89-S92
15. Yodono H, Takekawa SD, Tarusawa K, Ikami L Kanehira J, Saito Y, Takahashi S, Sasaki T, Nishi N, Kimura T. Combination therapy consisting of arterial infusion chemotherapy (EPF, EAP) and transcatheter arterial embolization (TAE). Cancer Chemother Pharmacol 1994; 33 Suppl: S79-S83
16. Wierzbicki R, Ezzat A, Abdel-Warith A, Ayoub A, Kagevi I, Fadda M, Sieck J, Abdulkareem M, Amin T, Yazigi A. Phase II trial of chronic daily VP-16 administration in unresectable hepatocellular carcinoma (HCC). Ann Oncol 1994; 5:466-467
17. Casanova M, Massimino M, Ferrari A, Spreafico F, Piva L, Coppa J, Luksch R, Cefalo G, Terenziani M, Polastri D, Bellani FF, Mazzaferro V. Etoposide, cisplatin, epirubicin chemotherapy in the treatment of pediatric liver tumors. Pediatr Hematol Oncol 2005; 22:189-198
18. Aita P, Robieux I, Sorio R, Tumolo S, Corona G, Cannizzaro R, Colussi AM, Boiocchi M, Toffoli G. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. Cancer Chemother Pharmacol 1999; 43:287-294
19. Bobbio-Pallavicini E, Porta C, Moroni M, Bertulezzi G, Civelli L, Pugliese P, Nastasi G. Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: a phase II study. Eur J Cancer 1997; 33:1784-1788
20. Melia WM, Johnson PJ, Williams R. Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin. Cancer 1983; 51:206-210
21. Sangro B, Rios R, Bilbao I, Beloqui O, Herrero JI, Quiroga J, Prieto J. Efficacy and toxicity of intra-arterial cisplatin and etoposide for advanced hepatocellular carcinoma. Oncology 2002; 62:293-298
22. Akimoto M, Yoshikawa M, Ebara M, Sato T, Fukuda H, Kondo F, Saisho H. Relationship between therapeutic efficacy of arterial infusion chemotherapy and expression of P-glycoprotein and p53 protein in advanced hepatocellular carcinoma. World J Gastroenterol 2006; 12:868-873
23. Yamashita F, Tanaka M, Andou E, Yutani S, Kato O, Tanikawa K. Carboplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Oncology 1997; 54:28-33
24. Kim SJ, Seo HY, Choi JG, Sul HR, Sung HJ, Park KH, Choi IK, Oh SC, Yoon SY, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS. Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2006; 57:436-442
25. Boucher E, Corbinais S, Brissot P, Boudjema K, Raoul JL. Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). Cancer Chemother Pharmacol 2002; 50:305-308
26. Pohl J, Zuna I, Stremmel W, Rudi J. Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma. Chemotherapy 2001; 47:359-365
27. Dobbs NA, Twelves CJ, Rizzi P, Warwick JD, Metivier EM, Williams R, Johnson PJ. Epirubicin in hepatocellular carcinoma: pharmacokinetics and clinical activity. Cancer Chemother Pharmacol 1994; 34:405-410
28. Kusunoki M, Yanagi H, Kotera H, Noda M, Yamamura T. Effects of pharmacokinetic modulating chemotherapy using oral UFT and continuous venous 5FU infusion on the prognosis of irradiated rectal carcinomas with p53 overexpression. Int J Oncol 1998; 13:653-657
29. Kusunoki M, Yanagi H, Noda M, Yoshikawa R, Yamamura T. Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases. Cancer 2000; 89:1228-1235
30. Kamiyama T, Matsushita M, Kurauchi N, Nakagawa T, Kamachi H, Kondo M, Ito T, Ogata T, Nishikawa M, Todo S. Modified pharmacokinetic modulation chemotherapy (PMC) with medication of UFT and intraarterial infusion of 5-FU for advanced unresectable HCC. Gan To Kagaku Ryoho 2002; 29: 2527-2531